参考文献/References:
[1] 胡盛寿,高润霖,刘力生,等。《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.[2] McDonagh TA,Metra M,Adamo M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42(36):3599-3726.[3] Sharma P,Sampath H.Mitochondrial DNA integrity:role in health and disease[J].Cells,2019,8(2):100.[4] Kunkel GH,Chaturvedi P,Tyagi SC.Mitochondrial pathways to cardiac recovery:TFAM[J].Heart Fail Rev,2016,21(5):499-517.[5] Chew K,Zhao L.Interactions of mitochondrial transcription factor A with DNA damage:mechanistic insights and functional implications[J].Genes (Basel),2021,12(8):1246[6] Koh JH,Kim YW,Seo DY,et al.Mitochondrial TFAM as a signaling regulator between cellular organelles:a perspective on metabolic diseases[J].Diabetes Metab J,2021,45(6):853-865.[7] Zhou B,Tian R.Mitochondrial dysfunction in pathophysiology of heart failure[J].J Clin Invest,2018,128(9):3716-3726.[8] van der Pol A,van Gilst WH,Voors AA,et al.Treating oxidative stress in heart failure:past,present and future[J].Eur J Heart Fail,2019,21(4):425-435.[9] Quan Y,Xin Y,Tian G,et al.Mitochondrial ROS-modulated mtDNA:a potential target for cardiac aging[J].Oxid Med Cell Longev,2020,2020:9423593.[10] Santulli G,Xie W,Reiken SR,et al.Mitochondrial calcium overload is a key determinant in heart failure[J].Proc Natl Acad Sci U S A,2015,112(36):11389-11394.[11] Liu J,Zhao Y,Zhu Y,et al.Rhynchophylline regulates calcium homeostasis by antagonizing ryanodine receptor 2 phosphorylation to improve diabetic cardiomyopathy[J].Front Pharmacol,2022,13:882198.[12] Garbincius J,Luongo T,Jadiya P,et al.Enhanced NCLX-dependent mitochondrial Ca efflux attenuates pathological remodeling in heart failure[J].J Mol Cell Cardiol,2022,167:52-66.[13] Cheriyan A,Ume A,Francis C,et al.Calcineurin A-α suppression drives nuclear factor-κB-mediated NADPH oxidase-2 upregulation[J].Am J Physiol Renal Physiol,2021,320(5):789-798.[14] Chaklader M,Rothermel BA.Calcineurin in the heart:new horizons for an old friend[J].Cell Signal,2021,87:110134.[15] Cabral-Pacheco GA,Garza-Veloz I,Castruita-De la Rosa C,et al.The roles of matrix metalloproteinases and their inhibitors in human diseases[J].Int J Mol Sci,2020,21(24):9739.[16] Zhang M,Wang G,Peng T.Calpain-mediated mitochondrial damage:an emerging mechanism contributing to cardiac disease[J].Cells,2021,10(8):2024.[17] Kunkel GH,Kunkel CJ,Ozuna H,et al.TFAM overexpression reduces pathological cardiac remodeling[J].Mol Cell Biochem,2019,454(1-2):139-152.[18] Zhihao L,Jingyu N,Lan L,et al.SERCA2a:a key protein in the Ca(2+) cycle of the heart failure[J].Heart Fail Rev,2020,25(3):523-535.[19] Aluja D,Delgado-Tomas S,Ruiz-Meana M,et al.Calpains as potential therapeutic targets for myocardial hypertrophy[J].Int J Mol Sci,2022,23(8):4103.[20] Williams R,Johnson C.A review of calcineurin biophysics with implications for cardiac physiology[J].Int J Mol Sci,2021,22(21):11565.[21] Lin J,Chen Z,Yang L,et al.Cas9/AAV9-mediated somatic mutagenesis uncovered the cell-autonomous role of sarcoplasmic/endoplasmic reticulum calcium ATPase 2 in murine cardiomyocyte maturation[J].Front Cell Dev Biol,2022,10:864516.[22] Watanabe A,Arai M,Koitabashi N,et al.Mitochondrial transcription factors TFAM and TFB2M regulate Serca2 gene transcription[J].Cardiovasc Res,2011,90(1):57-67.[23] Yang J,Chen W,Zhang B,et al.Lon in maintaining mitochondrial and endoplasmic reticulum homeostasis[J].Arch Toxicol,2018,92(6):1913-1923.[24] Matsushima Y,Goto Y,Kaguni L.Mitochondrial Lon protease regulates mitochondrial DNA copy number and transcription by selective degradation of mitochondrial transcription factor A (TFAM)[J].Proc Natl Acad Sci U S A,2010,107(43):18410-18415.[25] Lan L,Guo M,Ai Y,et al.Tetramethylpyrazine blocks TFAM degradation and up-regulates mitochondrial DNA copy number by interacting with TFAM[J].Bioscience reports,2017,37(3):BSR20170319.[26] Kao T,Chiu Y,Fang W,et al.Mitochondrial Lon regulates apoptosis through the association with Hsp60-mtHsp70 complex[J].Cell Death Dis,2015,6(2):e1642.[27] Li Y,Jiao Y,Liu Y,et al.PGC-1α protects from myocardial ischaemia-reperfusion injury by regulating mitonuclear communication[J].J Cell Mol Med,2022,26(3):593-600.[28] Zhu Z,Li H,Chen W,et al.Perindopril improves cardiac function by enhancing the expression of SIRT3 and PGC-1α in a rat model of isoproterenol-induced cardiomyopathy[J].Front Pharmacol,2020,11:94.[29] Yao K,Zhang WW,Yao L,et al.Carvedilol promotes mitochondrial biogenesis by regulating the PGC-1/TFAM pathway in human umbilical vein endothelial cells (HUVECs)[J].Biochem Biophys Res Commun,2016,470(4):961-966.[30] Hou N,Huang Y,Cai SA,et al.Puerarin ameliorated pressure overload-induced cardiac hypertrophy in ovariectomized rats through activation of the PPARalpha/PGC-1 pathway[J].Acta Pharmacol Sin,2021,42(1):55-67.[31] He H,Li C,Lu X,et al.RNA-Seq profiling to investigate the mechanism of qishen granules on regulating mitochondrial energy metabolism of heart failure in rats[J].Evid Based Complement Alternat Med,2021,2021:5779307.[32] Qui?nes-Lombra? A,Blanco J.Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM)[J].Biochim Biophys Acta,2015,1852(7):1420-1427.[33] Wu K,Ma J,Zhan Y,et al.Down-regulation of microRNA-214 contributed to the enhanced mitochondrial transcription factor a and inhibited proliferation of colorectal cancer cells[J].Cell Physiol Biochem,2018,49(2):545-554.[34] Zuo Y,Qu C,Tian Y,et al.The HIF-1/SNHG1/miR-199a-3p/TFAM axis explains tumor angiogenesis and metastasis under hypoxic conditions in breast cancer[J].Biofactors,2021,47(3):444-460.[35] Peng H,Guo T,Chen Z,et al.Hypermethylation of mitochondrial transcription factor A induced by cigarette smoke is associated with chronic obstructive pulmonary disease[J].Exp Lung Res,2019,45:101-111.[36] Behera J,Ison J,Voor M,et al.Probiotics stimulate bone formation in obese mice via histone methylations[J].Theranostics,2021,11(17):8605-8623.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(10):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(10):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(10):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(10):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(10):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(10):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(10):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(10):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(10):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(10):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]